Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
earnings date
Key Terms
rett syndromemedical
A rare genetic disorder that disrupts normal brain development in young children, most commonly girls, leading to slowed growth, loss of purposeful hand use, repetitive hand movements, motor problems, speech loss, and cognitive and breathing irregularities. Investors watch it because its severity and few treatment options create clear medical need and potential markets for therapies; think of it as a broken traffic signal in the brain that, if fixed, could restore many downstream functions.
parkinson’s disease psychosismedical
A complication of Parkinson’s disease in which people experience hallucinations, false beliefs, or confused thinking that arise from the illness itself or as a side effect of its treatments. It matters to investors because it creates a distinct medical need and market for safer therapies, influences clinical trial design and regulatory review, and can affect healthcare costs and drug sales; think of it as a car’s warning lights misfiring, prompting demand for better, more reliable fixes.
alzheimer’s disease psychosismedical
A set of hallucinations, false beliefs or related behavioral disturbances that occur in some people with Alzheimer’s disease, making memory loss and confusion worse and often increasing caregiving needs. It matters to investors because these symptoms represent a clear unmet medical need that drives clinical trials, regulatory review and potential drug sales; a treatment that safely reduces psychosis can change patient care patterns, lower long‑term costs and create significant market value, like fixing a major complication that suddenly makes a chronic problem much harder to manage.
lewy body dementia psychosismedical
Lewy body dementia psychosis is the set of hallucinations, false beliefs and severe confusion that can occur in people with Lewy body dementia, a progressive brain disorder marked by abnormal protein clumps in nerve cells. It matters to investors because these behavioral symptoms shape the need for treatments, influence clinical trial design and regulatory approval, and drive long‑term care costs and market size—like a key product feature that determines demand and safety scrutiny.
fda-approvedregulatory
FDA-approved means a medical product, drug, device or treatment has passed the U.S. Food and Drug Administration’s review for safety and effectiveness for a specific use. Think of it like a formal safety and performance seal that allows the product to be marketed for that purpose in the U.S.; for investors, approval reduces regulatory uncertainty, enables sales and reimbursement pathways, and can materially affect a company’s revenue prospects and valuation.
Company to host conference call and webcast on Wednesday, February 25, 2026, at 4:30 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on February 25, 2026, at 4:30 p.m. Eastern Time.
The conference call will be available on Acadia’s website, acadia.com under the investors section and will be archived there until May 24, 2026. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.
About Acadia Pharmaceuticals
Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X.
